Full Title
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti- Leukemia or anti-MDS Activity of RPT1G in Patients with Acute Myeloid Leukemia (AML) and Higher-Risk (HR) Myelodysplastic Syndromes/Neoplasms (MDS)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.
Protocol
26-093
Phase
Phase I (phase 1)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
ClinicalTrials.gov ID
NCT07107126